Filing Details

Accession Number:
0001209191-10-020349
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-04-02 13:00:00
Reporting Period:
2010-03-31
Filing Date:
2010-04-02
Accepted Time:
2010-04-02 18:45:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1012140 Onyx Pharmaceuticals Inc ONXX Biological Products, (No Disgnostic Substances) (2836) 943154463
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1365619 Laura Brege C/O Onyx Pharmaceuticals, Inc.
2100 Powell Street
Emeryville CA 94608
Evp And Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-03-31 8,000 $0.00 25,793 No 4 A Direct
Common Stock Disposition 2010-03-31 3,333 $30.15 22,460 No 4 S Direct
Common Stock Disposition 2010-04-01 4,334 $30.10 18,126 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (RIght to Buy) Acquisiton 2010-03-31 56,000 $0.00 56,000 $30.28
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
56,000 2020-03-31 No 4 A Direct
Footnotes
  1. Shares sold pursuant to a 10b5-1 plan.
  2. 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.